pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Pulmonology · news · pharmadog
← back to Pulmonology
News · Pulmonology
723
stories
8h
STAT+: Influential preventive services panel to meet for first time in more than a year
stat
15h
Merck scraps centerpiece of $2.7B ArQule buy after late-stage safety concerns
biospace
15h
STAT+: FDA discloses reasons for rejecting Summit drug
stat
15h
STAT+: Pharmalittle: We’re reading about Overton FDA nomination being yanked, a Merck setback, and more
stat
15h
FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK
biopharma dive
16h
GSK nabs FDA greenlight for second lung cancer asset from Nuvalent buy
biospace
17h
Summit’s rejection letter reveals FDA’s deeper concerns about trial design, safety
biospace
19h
Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlight
biospace
21h
Pfizer enters in vivo CAR-T space via 3-program, $2.6B deal with China’s Starna
fiercebiotech
1d
5 acquisitions that forced Big Pharmas to co-parent
biospace
1d
GSK’s Nuvalent buyout delivers again as FDA clears Nelkarmi for lung cancer
endpoints
1d
FDA’s complete response letter for Summit’s ivonescimab cites China-heavy data beyond survival miss
fiercebiotech
1d
AstraZeneca, Calidi, Tempest make significant workforce cuts
biospace
2d
STAT+: In a win for MAHA, FDA creates new regulatory category for the supplement NAC
stat
2d
Summit shares fall as FDA rejects closely watched PD-1/VEGF drug
biopharma dive
2d
FDA’s Summit rejection puts PD-1xVEGF class on notice to establish overall survival
biospace
2d
STAT+: Helus’ psychedelic drug improved depression in study but faces safety questions
stat
2d
STAT+: Bladder cancer immunotherapy from CG Oncology reduced risk of tumor recurrence
stat
2d
STAT+: Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues
stat
2d
BeOne, Hengrui top list of China’s most powerful drugmakers
stat
2d
One of Europe’s leading VCs banks a €725M ‘crossover’ fund
biopharma dive
3d
STAT+: Apple and OpenEvidence launch experimental health chat app
stat
3d
Recon: FDA rejects ivonescimab for lung cancer indication; J&J to buy eye disease biotech Ollin Biosciences for up to $3.3B
raps
3d
STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics
stat
3d
Summit's PD-1xVEGF rejected by FDA in lung cancer
biospace
3d
FDA rejects Summit, Akeso's ivonescimab in narrow lung cancer setting
endpoints
5d
Windward Bio hits Nasdaq with $175M IPO, plus another $50M from Sanofi
endpoints
5d
Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earnings
biospace
5d
Windward nets $175M IPO, bringing 2026 biotech debuts to 35
biospace
5d
Opinion: New organ donation rules are unfair to families
stat
← prev
page 1 of 25
next →